Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia

Ceftolozane/tazobactam is an antipseudomonal antibacterial approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intra‐abdominal infections (cIAIs) and in phase 3 clinical development for treatment of nosocomial pneumonia. A population pharmacokinetic (PK) model...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Alan J., Miller, Benjamin W., Huntington, Jennifer A., Nicolau, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049594/
https://www.ncbi.nlm.nih.gov/pubmed/26096377
http://dx.doi.org/10.1002/jcph.566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049594/
https://www.ncbi.nlm.nih.gov/pubmed/26096377
http://dx.doi.org/10.1002/jcph.566

Ejemplares similares